TTI1 Antibody

What is TTI1 and why is it important in cellular biology?

TTI1 (TELO2-Interacting Protein 1 Homolog) is a critical component of the Triple T (TTT) complex that includes TELO2 and TTI2. This evolutionarily conserved complex plays an essential role in modulating the activity of phosphatidylinositol 3-kinase-related protein kinases (PIKKs), including mTOR, ATM, and ATR. The TTT complex specifically regulates the assembly of mTOR complex 1 (mTORC1) and is crucial for the expression, maturation, and stability of ATM and ATR in response to DNA damage . Recent research has identified that bi-allelic pathogenic variants in TTI1 can cause an autosomal-recessive disorder, establishing it as the third TTT-related disorder known to medical science . Understanding TTI1 function is particularly important because it interacts with and stabilizes all six members of the PIKK family of proteins (mTOR, ATM, ATR, DNA-PKcs, SMG-1, and TRRAP), which are central to cellular processes including nutrient sensing, DNA damage response, and cell growth regulation .

What experimental applications can TTI1 antibodies be used for?

TTI1 antibodies have multiple applications in molecular and cellular biology research:

For optimal results, researchers should validate specific dilutions for their experimental conditions . TTI1 antibodies have been successfully employed in studies examining protein-protein interactions within the TTT complex and between TTI1 and PIKKs. They are particularly valuable in experiments assessing changes in TTI1 expression levels following genetic manipulation or cellular stress. Immunofluorescence applications, while not explicitly mentioned in the provided data, may also be possible with appropriate validation, enabling researchers to visualize the subcellular localization of TTI1 in various cell types.

How do I validate TTI1 antibody specificity for my experiments?

Validating TTI1 antibody specificity is crucial for reliable experimental results. A systematic approach includes multiple complementary methods. First, perform Western blot analysis comparing wild-type cells with cells where TTI1 has been knocked down via siRNA or CRISPR-Cas9. The disappearance or significant reduction of the TTI1 band (approximately 200 kDa) in knockout/knockdown samples confirms antibody specificity . Second, conduct immunoprecipitation experiments with your TTI1 antibody followed by mass spectrometry to verify that TTI1 is the predominant protein isolated. Additionally, detection of known TTI1 binding partners like TELO2 and TTI2 in the immunoprecipitate provides further validation .

Use positive controls such as HEK293T cells overexpressing FLAG-tagged TTI1, as these have been established in the literature as reliable systems for TTI1 detection . When testing new antibody lots, always run them alongside previously validated antibodies to ensure consistent performance. It's also advisable to test the antibody across multiple cell lines to confirm consistent detection patterns. Remember that buffer conditions can significantly affect TTI1 protein complex stability—use CHAPS-containing buffers rather than Triton X-100 for immunoprecipitation experiments, as the latter can disrupt TTI1's interaction with binding partners like mTOR .

How can I optimize TTI1 antibody use for detecting protein-protein interactions within the TTT complex?

Optimizing TTI1 antibody use for protein-protein interaction studies requires careful consideration of buffer composition and experimental conditions. The interaction between TTI1 and other proteins, particularly mTOR, is sensitive to detergent type. Use CHAPS-containing buffer (0.3% CHAPS) rather than Triton X-100, as the latter disrupts TTI1's interactions with mTOR and potentially other binding partners . For immunoprecipitation experiments, a buffer containing 40 mM HEPES (pH 7.5), 150 mM NaCl, 2 mM EDTA, and 0.3% CHAPS has been successfully used to maintain these interactions .

When studying endogenous interactions, be aware that only a small population of endogenous TTI1 associates with mTOR compared to the strong association observed between mTOR and Raptor/Rictor . This may necessitate optimizing protein amounts and exposure times for detection. For examining TTI1's interactions with multiple partners simultaneously, consider techniques like size-exclusion chromatography followed by immunoblotting of fractions. This approach has successfully demonstrated that components of mTOR complexes (mTOR, Raptor, Rictor, and mLST8) co-elute with TTI1 in high molecular weight fractions (>600 kDa) . Advanced techniques like SiMPull (single-molecule pulldown) can provide quantitative information about stoichiometry in TTI1-containing complexes, as demonstrated in studies of TTI1 variants and their impact on mTORC1 assembly .

What are the best methods for studying TTI1's role in mTOR pathway regulation using TTI1 antibodies?

To effectively study TTI1's role in mTOR pathway regulation, several complementary approaches can be employed. First, knockdown TTI1 using siRNA (demonstrated to reduce TTI1 to nearly undetectable levels) and assess changes in mTORC1 and mTORC2 activities . For mTORC1, monitor phosphorylation of S6K1 (Thr389) and 4E-BP1 (multiple sites) following amino acid stimulation. For mTORC2, examine Akt phosphorylation at Ser473 after serum replenishment . Additionally, autophagy regulation can be assessed through the LC3 conversion assay, as TTI1 depletion has been shown to affect autophagy control in response to amino acid availability .

To examine complex assembly, perform co-immunoprecipitation experiments with anti-mTOR antibodies followed by immunoblotting for Raptor (mTORC1) and Rictor (mTORC2). TTI1 depletion markedly reduces co-precipitation of these components, indicating complex disassembly . For higher resolution analysis, size-exclusion chromatography of cytosolic fractions can be used to monitor shifts in the elution profiles of mTOR complex components. In control cells, these proteins predominantly elute in fractions corresponding to >600 kDa, while TTI1 knockdown disrupts this pattern . When interpreting results, consider that TTI1 depletion not only affects complex assembly but also slightly reduces mTOR protein levels due to its role in PIKK stability. For conclusive interpretations, normalize phosphorylation data to total protein levels and include appropriate controls for both knockdown efficiency and pathway specificity.

How can I use TTI1 antibodies to investigate DNA damage response pathways?

TTI1 antibodies are valuable tools for investigating DNA damage response pathways due to TTI1's critical role in regulating ATM and ATR, key kinases in DNA damage signaling. To study this function, expose cells to UV radiation and analyze phosphorylation levels of ATM/ATR-mediated DNA damage response substrates at defined timepoints (e.g., 60 minutes post-exposure) . Immunoblotting with phospho-specific antibodies against ATM/ATR substrates, alongside total protein controls, can reveal how TTI1 manipulation affects the DNA damage response cascade.

For more detailed analysis of repair kinetics, expose cells to UV radiation and fix them at different time points to measure the clearance of DNA damage markers, such as 6-4 photoproducts (6-4PP) . By comparing wild-type cells with those expressing TTI1 variants or following TTI1 knockdown, you can assess TTI1's contribution to DNA repair efficiency. Additionally, lymphoblastoid cell lines (LCLs) derived from individuals with TTI1 variants have been successfully used to evaluate ATM levels and activity by immunoblotting and kinase assays . When designing these experiments, include positive and negative controls, such as LCLs from normal individuals and those with classical ataxia-telangiectasia (A-T), respectively. For comprehensive pathway analysis, examine multiple PIKK family members (ATM, ATR, DNA-PKcs, SMG-1) to determine whether TTI1 manipulation differentially affects these related kinases, as TTI1 has been shown to impact the stability of all PIKK family proteins .

What factors should be considered when selecting between polyclonal and monoclonal TTI1 antibodies?

When selecting between polyclonal and monoclonal TTI1 antibodies, researchers should consider several experimental requirements. Polyclonal TTI1 antibodies, such as the rabbit polyclonal antibody described in the available data, recognize multiple epitopes of the TTI1 protein, potentially providing higher sensitivity for detection of low-abundance TTI1 . This multi-epitope recognition can be advantageous in applications like Western blotting and immunoprecipitation, especially when protein conformation may be altered during experimental procedures. Additionally, polyclonal antibodies might better tolerate minor changes in the protein structure that could occur due to genetic variants or post-translational modifications.

In contrast, monoclonal antibodies (not specifically described in the provided search results, but important for comparison) offer higher specificity for a single epitope, which can reduce background and cross-reactivity in applications requiring precise detection. For experiments involving quantitative comparisons across multiple samples or when absolute specificity is required, monoclonal antibodies may be preferable. When studying TTI1 variants with specific mutations, it's crucial to consider whether these mutations might affect antibody recognition sites. For example, structural studies using cryo-EM and AlphaFold2 predictions have been employed to analyze TTI1 variants , suggesting that certain mutations might alter protein folding and potentially affect epitope accessibility. Ultimately, the choice between polyclonal and monoclonal antibodies should be guided by the specific research question, required sensitivity, specificity considerations, and the particular application being used.

How can I adapt TTI1 antibody-based methods for studying TTI1 variants associated with human disorders?

Adapting TTI1 antibody-based methods for studying disease-associated TTI1 variants requires several methodological considerations. First, evaluate whether the variants affect the epitope recognized by your antibody. For variants identified in patients, test antibody recognition using overexpression systems in HEK293T cells, comparing detection of wild-type and variant TTI1 by both anti-TTI1 and epitope-tag antibodies (e.g., FLAG) . This approach can distinguish between alterations in antibody recognition versus actual protein expression or stability differences.

For functional studies, implement a multi-method approach as demonstrated in recent research on TTI1-related disorders. This includes examining protein stability using immunoblotting, protein-protein interactions via co-immunoprecipitation, and complex formation through techniques like SiMPull . To assess variant impact on TTI1's role in PIKK stability, monitor levels of all six PIKK family members (mTOR, ATM, ATR, DNA-PKcs, SMG-1, and TRRAP) in cells expressing TTI1 variants compared to wild-type controls . For more detailed mechanistic insights, combine antibody-based detection with functional readouts such as mTOR signaling (via S6K1, 4E-BP1, and Akt phosphorylation assays) and DNA damage response (via ATM/ATR substrate phosphorylation) .

When studying patient-derived samples, lymphoblastoid cell lines (LCLs) have been successfully employed to evaluate TTI1 variant effects on TTT complex formation and PIKK stability . These cells can be generated by exposing lymphocytes from patient blood samples to EBV virus for transformation, providing a renewable source of patient-specific material for extended studies. For all experiments with disease-associated variants, include appropriate controls such as wild-type TTI1 and, when possible, known pathogenic variants with characterized effects for comparative analysis.

What are the recommended protocols for using TTI1 antibodies in size-exclusion chromatography and gel filtration studies?

For size-exclusion chromatography and gel filtration studies using TTI1 antibodies, a carefully optimized protocol is essential to maintain protein complex integrity while achieving good separation. Begin by preparing cells using a hypotonic lysis buffer containing 40 mM Tris-HCl (pH 7.5) supplemented with Complete EDTA-free protease inhibitor . Cell disruption should be gentle to preserve complexes—lysing cells through repeated passage (approximately 15 times) through a 1-ml syringe with a 27-gauge needle is effective . Following initial low-speed centrifugation (2,000 rpm for 5 minutes), ultracentrifuge the supernatant at high speed (43,000 rpm for 30 minutes) to remove membrane components and debris .

Apply the clarified cytosolic fraction to a Superose 6 column, which provides good resolution in the high molecular weight range where TTI1-containing complexes elute (>600 kDa) . For optimal separation, use a flow rate of 0.5 ml/min with a buffer containing 40 mM Tris-HCl (pH 7.5) and 150 mM NaCl . Collect fractions of approximately 0.5 ml each for subsequent analysis. For calibration, use a mixture of standards including thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232 kDa), albumin (67 kDa), ovalbumin (43 kDa), and cytochrome c (12.5 kDa) .

After collection, analyze the fractions by immunoblotting with antibodies against TTI1 and its binding partners (TELO2, TTI2, mTOR, Raptor, Rictor, and mLST8). To enhance detection sensitivity, consider concentrating fractions using methods such as TCA precipitation or centrifugal filter units prior to SDS-PAGE. When interpreting results, compare elution profiles across multiple proteins to identify co-eluting complexes. Shifts in these profiles under different experimental conditions (e.g., following TTI1 knockdown or mutation) can provide valuable insights into complex assembly and stability. This approach has successfully demonstrated that components of mTOR complexes predominantly elute in high molecular weight fractions when intact, but show altered elution patterns when TTI1 is depleted .

How can TTI1 antibodies be utilized in emerging single-molecule techniques for protein complex analysis?

TTI1 antibodies can be powerfully integrated with emerging single-molecule techniques to provide unprecedented insights into protein complex dynamics and stoichiometry. Single-molecule pulldown (SiMPull) has already been successfully employed to study TTI1 variants and their impact on mTORC1 formation . This technique combines the specificity of antibody-based pulldown with single-molecule fluorescence imaging. To implement this approach, researchers should immobilize anti-FLAG antibodies (when using FLAG-tagged TTI1) or anti-TTI1 antibodies on quartz slides, then apply cell lysates containing fluorescently tagged interaction partners (e.g., GFP-mTOR and RFP-Raptor) . Total internal reflection fluorescence (TIRF) microscopy can then be used to visualize and count individual molecular complexes.

SiMPull photobleaching analysis enables determination of stoichiometry within TTI1-containing complexes, as demonstrated in studies assessing mTOR oligomeric state and mTORC1 composition associated with TTI1 variants . For precise quantification, careful attention must be paid to background fluorescence reduction and photobleaching step analysis. Beyond SiMPull, TTI1 antibodies could be adapted for other emerging techniques such as single-molecule Förster resonance energy transfer (smFRET) to monitor conformational changes in TTI1-containing complexes in real-time. Additionally, techniques like stochastic optical reconstruction microscopy (STORM) or photoactivated localization microscopy (PALM) combined with TTI1-specific antibodies could reveal the nanoscale organization of TTI1-containing complexes within cells at previously unattainable resolution. For all these applications, antibody validation is crucial, and pilot experiments comparing wild-type and TTI1-depleted samples should be conducted to confirm specificity at the single-molecule level.

What approaches can be used to study temporal dynamics of TTI1 interactions using TTI1 antibodies?

Studying the temporal dynamics of TTI1 interactions requires techniques that can capture protein complex formation and dissociation in real-time or across defined timepoints. Several methodological approaches can be adapted for this purpose using TTI1 antibodies. First, researchers can employ a cell synchronization strategy followed by time-course analysis. This has been demonstrated using a dual-reporter system with H2B-mCherry and DHB-GFP to monitor cell cycle progression in cells expressing FLAG-TTI1 . Cells can be synchronized in G0 phase through serum deprivation for 24 hours, followed by serum stimulation and sample collection at defined intervals for immunoprecipitation and immunoblotting .

For studying TTI1's role in DNA damage response over time, cells can be exposed to UV radiation and then fixed or lysed at different timepoints for analysis of TTI1-containing complexes and their downstream effects . This approach has been used to assess both the immediate phosphorylation of ATM/ATR substrates and the repair kinetics of DNA lesions such as 6-4 photoproducts (6-4PP) . For more dynamic tracking of TTI1 interactions, proximity ligation assays (PLA) could be adapted using TTI1 antibodies paired with antibodies against interaction partners. This would allow visualization of specific protein-protein interactions within intact cells, with changes in PLA signal intensity over time reflecting interaction dynamics.

What are the critical quality control measures for long-term reliability of TTI1 antibody-based experiments?

Ensuring long-term reliability of TTI1 antibody-based experiments requires implementation of systematic quality control measures. First, establish rigorous validation protocols for each new antibody lot, including Western blot comparison between wild-type and TTI1-depleted samples to confirm specificity . Document band patterns and intensity across multiple cell types to create a reference standard for future comparisons. Store antibodies according to manufacturer recommendations (typically aliquoted and frozen at -20°C or -80°C) to prevent freeze-thaw cycles that could compromise activity.

Implement positive controls in all experiments, such as HEK293T cells overexpressing FLAG-tagged TTI1, which have been established as reliable systems for TTI1 detection . For quantitative applications, develop standard curves using recombinant TTI1 or cell lysates with known TTI1 expression levels. Track antibody performance over time by recording signal-to-noise ratios, detection limits, and consistency across replicates. Consider cross-validating critical results with alternative TTI1 antibodies recognizing different epitopes when available.

For immunoprecipitation experiments, monitor both the efficiency of TTI1 pulldown and the specificity by measuring the ratio of TTI1 to background proteins in immunoprecipitates . Regularly test for cross-reactivity with related proteins, particularly TTI2, which functions in the same complex. Finally, maintain detailed records of antibody performance across different applications, buffer conditions, and experimental contexts to identify any shifts in reliability over time. These measures collectively ensure that experimental outcomes reflect true biological phenomena rather than technical artifacts related to antibody performance.

How should researchers approach conflicting results when using different TTI1 antibodies?

When confronted with conflicting results from different TTI1 antibodies, researchers should employ a systematic troubleshooting approach to resolve discrepancies. First, thoroughly characterize each antibody's properties, including the immunogen used (e.g., full-length KIAA0406 versus specific peptide regions) , host species, clonality, and epitope location if known. This information can help identify whether discrepancies might result from differential epitope accessibility in various experimental conditions or protein conformations.

Next, perform side-by-side validation experiments with positive controls (TTI1-overexpressing cells) and negative controls (TTI1-knockdown cells) for each antibody to determine specificity and sensitivity profiles . If one antibody fails to detect TTI1 in knockdown samples while others show residual signal, this suggests differences in specificity. For complex biochemical studies, consider whether different antibodies might preferentially recognize TTI1 in specific complex states or subcellular locations. The TTT complex undergoes conformational changes when interacting with client proteins, which could affect epitope accessibility .

Examine the experimental conditions closely, particularly buffer composition, as TTI1 interactions are sensitive to detergent type (CHAPS versus Triton X-100) . Test whether discrepancies persist across multiple experimental approaches (WB, IP, ELISA) to distinguish application-specific issues from fundamental antibody differences . When possible, validate key findings using orthogonal techniques that don't rely on antibodies, such as mass spectrometry identification of immunoprecipitated proteins or functional assays measuring TTI1-dependent processes. Finally, when publishing results, clearly report which antibody was used for each experiment, including catalog numbers and dilutions, and acknowledge any discrepancies observed between different antibodies to improve reproducibility in the field.